Therapeutic cell carriers: A potential road to cure glioma

Expert Review of Neurotherapeutics

Volumn 14, Issue 6, 2014, Pages 651-660

  Young, Jacob S ^a   Kim, Julius W ^a   Ahmed, Atique U ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

brain cancer; cell carriers; gene therapy; glioblastoma multiforme; glioma; induced progenitor cells; mesenchymal stem cells; neural stem cells; oncolytic virotherapy; tumor tropism

Indexed keywords

ANTINEOPLASTIC AGENT;

BONE MARROW CELL; BRAIN CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER PROGNOSIS; CANCER THERAPY; DRUG DELIVERY SYSTEM; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION; GENOME; GLIOMA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MOLECULAR THERAPY; NEURAL STEM CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; TROPISM; TUMOR MICROENVIRONMENT; BIOLOGICAL THERAPY; BRAIN NEOPLASMS; PROCEDURES;

BRAIN NEOPLASMS; CELL- AND TISSUE-BASED THERAPY; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS;

EID: 84901445102     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.917964     Document Type: Review

References (94)

1. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
2. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012;117(6):1032-8
3. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16(8): 2443-9
4. Lesniak MS. Gene therapy for malignant glioma. Expert Rev Neurother 2006;6(4): 479-88
5. Tobias A, Ahmed A, Moon K-S, Lesniak MS. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatr 2013;84(2):213-22
6. Allhenn D, Boushehri MAS, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm 2012; 436(1-2):299-310
7. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 2009;9(10):1519-27
8. Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed Ex for cancer therapy. Mol Ther 2009;17(10): 1667-76
9. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000;97(23):12846-51
10. Murphy AM, Rabkin SD. Current status of gene therapy for brain tumors. Transl Res 2013;161(4):339-54
11. Frank RT, Najbauer J, Aboody KS. Concise Review: stem cells as an emerging platform for antibody therapy of cancer. Stem Cells 2010;28(11):2084-7
12. Roger M, Clavreul A, Venier-Julienne MC, et al. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011;32(8):2106-16
13. Temple S. The development of neural stem cells. Nature 2001;414(6859):112-17
14. Kranzler J, Tyler MA, Sonabend AM, et al. Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Curr Gene Ther 2009;9(5):389-95
15. Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther 2010;12(5):546-52
16. Müller FJ, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 2006;7(1):75-84
17. An JH, Lee SY, Jeon JY, et al. Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res 2009;8(6):2873-81
18. Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003;422(6933):688-94
19. Pluchino S, Gritti A, Blezer E, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol 2009; 66(3):343-54
20. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 2012;18(1):69-81
21. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009;16(2):262-78
22. Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2007;6(5):679-85
23. Thaci B, Ahmed AU, Ulasov IV, et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther 2012; 19(6):431-42
24. Cheng Y, Morshed R, Cheng SH, et al. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small 2013;9(24):4123-9
25. Germano IM, Uzzaman M, Benveniste RJ, et al. Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg 2006;105(1):88-95
26. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25(20):8809-23
27. Ehtesham M, Kabos P, Gutierrez MAR, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002;62(24):7170-4
28. Danks MK, Yoon KJ, Bush RA, et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007;67(1):22-5
29. Metz MZ, Gutova M, Lacey SF, et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med 2013;2(12):983-92
30. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6(2): e1000029
31. A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas. Available from: www.clinicaltrials. gov/ct2/resultsterm=NCT01172964&Search=Search
32. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012;64(8):739-48
33. Hu YL, Fu YH, Tabata Y, Gao JQ. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 2010;147(2): 154-62
34. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008;36(6):733-41
35. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65(8):3307-18
36. Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68(23):9614-23
37. Hu YL, Huang B, Zhang TY, et al. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection. Mol Pharm 2012;9(9):2698-709
38. Shah K. Stem cell therapeutics for cancer. John Wiley and Sons; NY, USA: 2013
39. Beckermann BM, Kallifatidis G, Groth A, et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 2008; 99(4):622-31
40. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25(11):2739-49
41. Huang J, Zhang Z, Guo J, et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010;106(11):1753-62
42. Komarova S, Kawakami Y, Stoff-Khalili MA, et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5(3): 755-66
43. Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26(3):831-41
44. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007;99(18):1410-14
45. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009;69(23): 8932-40
46. Garcá-Castro J, Alemany R, Cascalló M, et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther 2010;17(7): 476-83
47. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25(7):1737-45
48. Roger M, Clavreul A, Huynh NT, et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 2012;423(1):63-8
49. Dai T, Yang E, Sun Y, et al. Preparation and drug release mechanism of CTS-TAXNP-MSCs drug delivery system. Int J Pharm 2013;456(1):186-94
50. Chan J, O'Donoghue K, de la Fuente J, et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells 2005;23(1):93-102
51. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99(13):8932-7
52. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27(9):2320-30
53. Balyasnikova IV, Prasol MS, Ferguson SD, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther 2014;22(1):140-8
54. Kanehira M, Xin H, Hoshino K, et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 2007;14(11):894-903
55. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11(14):1155-64
56. Fei S, Qi X, Kedong S, et al. The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J Cancer Res Clin Oncol 2012;138(2):347-57
57. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006;15(11):865-74
58. Xin H, Kanehira M, Mizuguchi H, et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007;25(7):1618-26
59. Choi SA, Lee JY, Wang K-C, et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer 2012;48(1):129-37
60. Balyasnikova IV, Ferguson SD, Sengupta S, et al. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully Inhibit the growth of human xenograft malignant glioma. PLoS ONE 2010;5(3):e9750
61. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4(3):206-16
62. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449(7162):557-63
63. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365(18):1673-83
64. Akimoto K, Kimura K, Nagano M, et al. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev 2013;22(9):1370-86
65. Shi M, Li J, Liao L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 2007;92(7):897-904
66. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16(3):571-9
67. Levy O, Zhao W, Mortensen LJ, et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013 122(14): e23-32
68. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14(2):181-7
69. Liu L, Eckert MA, Riazifar H, et al. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? Stem Cells Int 2013;2013:435093
70. Dáz-Coránguez M, Segovia J, López-Ornelas A, et al. Transmigration of neural stem cells across the blood brain barrier induced by glioma cells. PLoS One 2013;8(4):e60655
71. Ahmed AU, Tyler MA, Thaci B, et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.Mol Pharm 2011;8(5):1559-72
72. Tabatabai G, Wick W, Weller M. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? Discov Med 2011;11(61):529-36
73. Varma NRS, Janic B, Iskander ASM, et al. Endothelial progenitor cells (EPCs) as gene carrier system for rat model of human glioma. PLoS One 2012;7(1):e30310
74. Tabatabai G, Hasenbach K, Herrmann C, et al. Glioma tropism of lentivirally transduced hematopoietic progenitor cells. Int J Oncol 2010;36(6):1409-17
75. Deng W, Jia J. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the 'Trojan horse' approach. Med Hypotheses 2008; 70(4):842-4
76. Dudek AZ. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Transl Res 2010;156(3):136-46
77. Alberti MO, Deshane JS, Chaplin DD, et al. A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism. Gene Ther 2013; 20(7):733-41
78. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999;5(6):1523-37
79. Lun XQ, Zhou H, Alain T, et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007;67(18):8818-27
80. Kim SM, Woo JS, Jeong CH, et al. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med 2014;3(2):172-82
81. Kim SM, Oh JH, Park SA, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010;28(12):2217-28
82. Tobias AL, Thaci B, Auffinger B, et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med 2013; 2(9):655-66
83. Rowntree RK, McNeish JD. Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery. Regen Med 2010; 5(4):557-68
84. Slettenaar VIF, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006;58(8):962-74
85. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005;42(7):799-809
86. Auffinger B, Morshed R, Tobias A, et al. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget 2013;4(3):378-96
87. Bos PD, Zhang XHF, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459(7249): 1005-9
88. Kauer TM, Figueiredo JL, Hingtgen S, Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci 2012;15(2):197-204
89. Mattis VB, Svendsen CN. Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol 2011; 10(4):383-94
90. Lee EX, Lam DH, Wu C, et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 2011;8(5):1515-24
91. Yamanaka S. A fresh look at iPS cells. Cell 2009;137(1):13-17
92. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008;14(1):199-208
93. Bhirde A, Xie J, Swierczewska M, Chen X. Nanoparticles for cell labeling. Nanoscale 2011;3(1):142-53
94. Pham W, Xie J, Gore JC. Tracking the migration of dendritic cells by in vivo optical imaging. Neoplasia 2007;9(12): 1130-7